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A B S T R A C T
An increased Mycobacterium tuberculosis burden inside the host leads to higher demand of response
proteins. This in turn results in metabolic shift and cellular stress, which is caused by the accumulation
and trafficking of these proteins within the endoplasmic reticulum (ER). To resolve this, cells trigger the
unfolded protein response (UPR), which is mainly mediated by binding immunoglobulin protein (BiP)/
glucose-regulated protein 78 (GRP78) chaperone, and this in turn upregulates its transcription. This
chaperone protein facilitates proper protein folding within the ER; however, it can also be passively
secreted into the extracellular environment or be expressed on cell surfaces attached to anchor
proteins and transmembrane proteins. This notion has been shown in studies on chronic inflammation,
including cancer and arthritis, with the detection of BiP-specific antibodies from different sample
types. The present study analysed secreted BiP from plasma samples collected from healthy
participants and patients with newly diagnosed tuberculosis (TBdx), seen over the course of TB
treatment at week 1 (W1), month 2 (M2), and month 6 (M6). The results revealed that during the initial
TB disease and treatment period, cells are subjected to stress conditions resulting in metabolic shifts,
which lead to the secretion of the intracellular UPR-mediating chaperone protein, BiP. This was
indicated by mean differences between TBdx (mean 40.88 ng/ml) and W1 (68.57 ng/ml) in the TB
participant groups. However, no difference was observed between the healthy group (mean 42.64 ng/
ml) and TBdx group (mean 40.88 ng/ml). Analysis of paired time-point visits revealed increased BiP
secretion during early TB treatment. The detection of BiP in plasma samples was found to decrease after
successful TB treatment to levels comparable to those in the healthy controls. Evaluation of BiP levels in
larger TB treatment studies may lead to the identification of a new target for early TB diagnosis and
host-directed immunotherapy.
© 2019 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Binding immunoglobulin protein (BiP), also referred to as
glucose-regulated protein 78 (GRP78), is an endoplasmic reticulum
(ER) chaperone protein that plays a crucial role in protein synthesis
by mediating proper protein folding through binding with
polypeptide structures entering the ER lumen (Maddalo et al.,
2012; Morris et al., 1997). Although BiP interacts with peptides, its
function is not required for the extracellular secretion of proteins.
This chaperone protein resides in the ER lumen, in an inactive state
attached to three membrane transducer proteins: inositol-* Corresponding author.
E-mail address: GL2@sun.ac.za (A.G. Loxton).
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reticulum kinase (PERK), and activating transcription factor 6 (ATF-
6). Activation of this chaperone occurs during conditions that cause
cellular stress (Gass et al., 2002), specifically on ER, triggering the
unfolded protein response (UPR), which has been reported as a cell
survival mechanism.
During the UPR, a series of events may occur, including possible
termination of transcription and translation, destruction of unfolded
or misfolded proteins through ubiquitination, and upregulation of
GRP78/BiP expression (Rao and Bredesen, 2004). Although this
response is chiefly mediated by BiP/GRP78, it also requires the
activity of the three signal transducers localized in the ER membrane
(IRE1, PERK, and ATF-6), which phosphorylates cytosol kinases, and
these metabolic pathways determine the fate of the cell during the
UPR by either promoting cell survival or apoptosis.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
niversity from ClinicalKey.com by Elsevier on October 21, 
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Figure 1. Plasma sample collection at specific time points. N = total number,
TB = tuberculosis, TBdx = TB diagnosis, W1 = week 1, M2 = month 2, and M6 =
month 6.
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this is mediated by the transcription factor YY1, which binds to the
promoter region of the BiP gene. This transcription factor also acts
as a cofactor for the activation of ATF-6, which is reported to be
essential during the initiation of the ER stress response (Bau-
meister et al., 2005). BiP upregulation has also been shown to be
influenced by the activity of some proinflammatory cytokines,
particularly tumour necrosis factor alpha (TNF-α) and interleukin
1β (IL-1β) (Yoo et al., 2012).
Research studies have also shown that during chronic
inflammation and prolonged ER stress, BiP can translocate to
other cell compartments such as the cell membrane where it can
become attached to transmembrane proteins or glycosylphopha-
tidylinositol (GPI) proteins. A study by Tsai et al. (2015) suggested
that BiP can also escape the ER lumen to other cell compartments
attached to recently synthesized proteins. This could imply that
during the UPR, BiP may be secreted into the extracellular fluids
through these processes, and it was shown that its substrate
binding activity was important in this regard (Tsai et al., 2015).
Previous studies have reported an association between cell-free
BiP and disease exacerbation; however these studies focused on
chronic diseases such as cancer and autoimmune disease (Bläss
et al., 2001; Bodman-Smith et al., 2003; Zhang et al., 2010).
Moreover, the mechanisms involved in the secretion of this
chaperone into the extracellular fluids are not clearly defined and it
is also thought to escape during membrane repair by ER vesicles
(Zhang et al., 2010). In an extracellular phase, this chaperone has
been shown to act as an autoantigen on immune cells and leads to
metabolic shifts that affect cell function (Bodman-Smith et al.,
2003). The presence of BiP in extracellular fluids has been shown in
different sample types including serum, plasma, and synovial fluid.
Varying disease outcomes have been associated with extracel-
lular BiP, which show it to be both beneficial and detrimental. It has
been reported that this chaperone protein is overexpressed in
rheumatoid arthritis (RA) through the detection of autoantibodies
secreted specifically against it. During RA, extracellular BiP has
been reported to upregulate anti-inflammatory responses and this
has previously been reported to be beneficial in resolving
inflammation (Corrigall et al., 2004). Contradictory results have
also been reported, with extracellular BiP being shown to enhance
the progression of RA in synoviocytes by promoting the prolifera-
tion of synoviocytes, which in turn enhance angiogenesis (Yoo
et al., 2012). Additionally, the presence of this chaperone protein in
the extracellular phase has been reported to enhance outcome of
RA by affecting the activity of cytotoxic T-cells (Bläss et al., 2001).
Similarly, BiP pathogenesis has been reported during cancer
inflammation and it has been suggested that the downregulation
of BiP synthesis and activity could be beneficial in resolving cancer
conditions by restricting the synthesis of vital proteins required by
the cancer cells (Schwarze and Rangnekar, 2010).
Immunological response modifications associated with this
chaperone protein have led to interest in research evaluating its
secretion during the anti-tuberculosis (TB) treatment period in
infected patients. Previous immunological response studies have
highlighted the dysfunctionality within the B-cell subset in
response to TB and this may in part be brought into play by the
extracellular matrix. Extracellular BiP binding may lead to
intracellular metabolic shifts that affect the expression of both
soluble proteins and cell surface proteins.
Materials and methods
Ethics statement
Ethical approval was obtained from the Health Research Ethics
Committee of Stellenbosch University (N05/11/187) and the City ofDownloaded for Anonymous User (n/a) at Stellenbosch Universi
2021. For personal use only. No other uses without permission.Cape Town City Health. The study was conducted in accordance
with the Declaration of Helsinki and International Conference on
Harmonisation guidelines. Written informed consent was
obtained from all study participants.
Sample description
Blood samples were collected from participants recruited in the
Sarepta area of Cape Town in the Western Cape region of South
Africa. Participants were of both sexes and were aged between 18
and 64 years. Plasma samples were collected from a total of 81
participants (Figure 1), of whom 42 were male and 39 were female.
Collected samples were placed into two groups: those from
healthy controls (32 participants) who had no indication of
Mycobacterium tuberculosis infection based on sputum culture, X-
ray, and Quantiferon interferon-gamma release assay (IGRA); and
those from patients with a diagnosis of active TB (TBdx, disease
group at diagnosis; 29 participants) who had a positive sputum
culture, X-ray, and signs and symptoms suggestive of TB disease. TB
patients were started on treatment and were followed up at three
time-points; week 1 (W1), month 2 (M2), and month 6 (M6).
Collected plasma samples were then stored at 80 C until
analysis.
Enzyme-linked immunosorbent assay (ELISA) analysis
Collected plasma samples were recovered from the biorepo-
sitory and analysed by ELISA. The samples included those from the
healthy controls (n = 32) and the TB disease group (n = 29 at
baseline (TB diagnosis); n = 8 for the W1 follow-up time-point;
n = 7 for the M2 follow-up time-point; n = 19 for the M6 follow-up
visit); in addition, 20 new participants were recruited at the M6
time-point.
Plasma samples were completely thawed at room tempera-
ture before ELISA analysis. They were then centrifuged at
1000  g for 5 min to pellet any particulate material that might
interfere with analyte binding. The Human GRP78 ELISA kit from
MyBioSource (MBS2533401; San Diego, USA), which has a
minimum sensitivity of 0.375 ng/ml and a detection range of
0.625–40 ng/ml, was used as per the manufacturer’s instructions.
The kit is specified to have no cross-reactivity or interference
between analogues and human GRP78. ELISA plates were read
using a Bio-Rad iMark Microplate reader (California, USA) at a
recommended wavelength of 450 nm.ty from ClinicalKey.com by Elsevier on October 21, 
 Copyright ©2021. Elsevier Inc. All rights reserved.
Figure 3. Increased levels of binding immunoglobulin protein (BiP) following 1
week of TB treatment. Sample pairs analysed for changes in BiP secretion 1 week
after the start of TB treatment. Statistical difference assessed through non-
parametric paired t-test (Wilcoxon matched pairs test), p = 0.0078; **p < 0.01.
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The optical density (OD) readings obtained were analysed using
GraphPad PRISM 7 for Windows (GraphPad Software, La Jolla,
California, USA; www.graphpad.com). BiP concentrations were
analysed for differential expression between groups using one-
way non-parametric analysis of variance (ANOVA), the Mann–
Whitney U-test, and the unpaired t-test.
Results
BiP levels remain unchanged at diagnosis of active TB compared to
healthy controls
Figure 2 shows that although BiP is an ER resident chaperone
protein, it can be secreted into the plasma in small quantities even
in healthy individuals. There was a statistically significant
difference in BiP secretion between the participant groups
(p = 0.0270), with the healthy group (mean 42.64 ng/ml) and the
TB patients at diagnosis (TBdx) (mean 40.88 ng/ml) having
comparable mean expression. BiP secretion was upregulated
during early TB treatment (W1), showing the highest mean of
68.57 ng/ml. Furthermore, the detection of BiP in the TB groups
decreased gradually over the course of TB treatment, approaching
the levels of the healthy group and the TBdx baseline group (Figure
2). In the second month of TB treatment (M2), BiP detection was
found to decrease (mean 60.92 ng/ml) and there was a further
decrease by month 6 (M6), as indicated by mean value of 37.42 ng/
ml. In contrast, no statistically significant difference was observed
between the healthy, TBdx, M2, and M6 groups.
Effect of TB treatment on follow-up participants between TBdx and W1
BiP upregulation was further illustrated in TB treatment follow-
up participant pairs (Figure 3, Table 1), which indicated direct
upregulation of this chaperone from respective individuals with a
detection range between 30.60 ng/ml and 65.57 ng/ml for TBdx and
between 60.18 ng/ml and 86.77 ng/ml for W1 anti-TB treatment.
This showed a significant difference (p = 0.0078) in BiP secretion
between these two time-point visits.
BiP levels remain unchanged from week 1 of TB treatment until the end
of therapy
The participant follow-up visit at month 2 of anti-TB treatment
showed no significant change in extracellular BiP detection
(Figure 4) with their respective diagnosis time point (p = 0.1563)Figure 2. Detection of secreted binding immunoglobulin protein (BiP) during TB
treatment and healthy states. Statistical difference analysis through non-parametric
one-way ANOVA, p = 0.0270. CTRL = healthy group, TBdx = TB treatment group at
diagnosis, W1 = week 1 treatment group, M2 = month 2 treatment group, and
M6 = month 6 treatment group; error bars show the mean with standard deviation.
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shown in Table 1. BiP detection at the end of anti-TB treatment
(month 6) indicated a detection range between 56.64 ng/ml and
73.45 ng/ml; this showed no significant difference with BiP
detection at TBdx (p = 0.4800) (Table 1).
Discussion
This study provides evidence that during TB disease treatment,
the UPR is activated, leading to upregulation of intracellular
mediators such as BiP, which in turn escape into the extracellular
phase. Activation of the UPR is regarded as a survival mechanism
used by cells to cope with a high demand of response proteins
during inflammation (Lin et al., 2007).
M. tuberculosis infection is classified into different infection
stages, with latent TB infection (LTBI) representing the early stage
of infection, in which the bacterium is thought to be contained
(Flynn and Chan, 2001). During this time, immune cells are
subjected to minimal metabolic shift, resulting in minimal stress
response activation; this is evident in the present study results by
the non-significant different in BiP secretion levels between
healthy participants and those diagnosed as positive for M.
tuberculosis infection via sputum culture, IGRA, and X-ray results.
This finding is comparable to those reported in other studies
performed on cancer and arthritis, which have shown that during
prolonged stress conditions, cells activate the UPR response
resulting in the secretion of intracellular ER chaperone proteins,
amongst which is BiP (Bodman-Smith et al., 2003; Zhang et al.,
2005). Although the mechanisms involved in this are not fully
elucidated, it has been suggested that the cells elude these
intracellular components through passive mechanisms during ER
vesicle translocation, or they can also be released in conjunction
with their protein substrates (Tsai et al., 2015).
M. tuberculosis has been shown to be able to manipulate and
avoid the innate immune responses and multiply within the host
(Raghuvanshi et al., 2010; Sia et al., 2015). This leads to an
increased bacterial burden, which may eventually activate the UPR
due to the high demand of immunoglobulins and metabolic shift.
This then leads to the secretion of these mediators into the
extracellular phase, where they affect the disease outcome.
However, pharmacological agents have also been implicated in
activating the UPR (Srinivasan et al., 2005). This may suggest that
TB treatment regimens also participate in the upregulation of the
UPR, as they need to be metabolized by cells, mainly liver cells, into
inactive forms before being eliminated from the body. This results
in metabolic shifts within the cells, which force them to upregulate
the transcription and synthesis of specific protein compounds toversity from ClinicalKey.com by Elsevier on October 21, 
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Table 1
TB treatment follow-up participants.
Variable Treatment groups Numbera Mean levels (ng/ml) SD p-Value 95% CI for the mean Minimum (ng/ml) Maximum (ng/ml)
Lower bound Upper bound
BiP TBdx 8 52 14.95 0.0078 36.5 64.5 30.60 65.57
Week 1b 8 67.91 8.78 60.57 75.25 60.18 86.77
TBdx 7 50.06 15.03 0.1563 36.16 63.96 30.60 62.74
Month 2b 7 60.92 2.10 58.98 62.86 58.41 64.80
TBdx 19 59.50 12.90 0.4800 52.87 66.13 30.60 79.36
Month 6b 19 64.59 4.43 62.31 66.87 56.64 73.45
TB, tuberculosis; SD, standard deviation; CI, confidence interval; BiP, binding immunoglobulin protein; TBdx, TB diagnosis.
a Number of participants.
b Week 1, month 2, and month 6 of TB treatment.
Figure 4. Paired time-point visits during TB treatment revealed increased secretion
of binding immunoglobulin protein (BiP) by TB treatment group. Statistical
difference assessed through non-parametric paired Friedman test, p = 0.0057.
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non could be correlated with the high secretion levels (Figure 2) of
this stress response protein during the initial treatment period,
which is also characterized by a sharp decline in bacterial numbers.
Even though BiP is upregulated during the initial metabolic shifts
(Bodman-Smith et al., 2004), transcription and protein synthesis
becomes stabilized with unchanged conditions or declines with
resolved inflammation. Theoretically, during the TB treatment
period, the decrease in bacterial burden over time should result in
a decreased metabolic demand from activated immune cells; this
correlates with the study findings, where extracellular BiP was
shown to stabilize and gradually decrease after week 1 of TB
treatment. Similarly, the switch of TB drugs after month 2 (from
four drugs to two) and decreased bacterial burden do not facilitate
further upregulation of the UPR; furthermore, in contrast to the
other drugs in the TB regimen, rifampicin is not metabolized in the
body, suggesting an even lower protein demand.
Although activation of the UPR is considered a cell survival
mechanism, it has also been shown that a prolonged response
triggers cell death through apoptotic pathways by upregulation of
the transcription factor C/EBP homologous protein (CHOP) (Mozos
et al., 2011). The latter can be beneficial for infection control, since
TB disease is caused by an intracellular pathogen and inducing
apoptosis results in cell death from within by limiting metabolite
flux, which is vital for M. tuberculosis survival. Apoptotic pathways
are known to prevent early cell membrane rupture, thus limiting
the spread of M. tuberculosis to uninfected cells. This is the opposite
of necrotic pathways, which are suggested to be utilized by the
pathogen in question to infect and reside in other immune cells.
Upregulation of BiP in the cellular microenvironment has been
shown to induce an anti-inflammatory response in immune cells,Downloaded for Anonymous User (n/a) at Stellenbosch Univer
2021. For personal use only. No other uses without permissioneither by upregulation of interleukin 10 (IL-10) synthesis (Yoshida
et al., 2011) or upregulation of surface markers involved in
programmed cell death (Tang et al., 2016).
This study evaluating the utility of secreted BiP over the course
of TB treatment must be seen as an preliminary investigation, as
the number of participants with active TB was relatively small. BiP
levels were detected with standard methods; however protein
degradation might have occurred over time, resulting in lower
levels of this biomarker. Future studies must evaluate BiP levels in a
larger collection of fresh plasma and serum samples from
participants at different stages of M. tuberculosis infection.
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